Abiopharma

🔍 Etergino Thomas J (Executive)

Company: 1stdibs.com, Inc. (DIBS)

Report Date: 2026-06-08

Detailed Transactions and Holdings:

• Acquired 11,175 shares of Common Stock (Direct)
  Date: 2026-06-08 | Code: M | equity_swap_involved: 0 | shares_owned_after: 311,960.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 11,172 shares of Common Stock (Direct)
  Date: 2026-06-08 | Code: M | equity_swap_involved: 0 | shares_owned_after: 323,132.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 12,125 shares of Common Stock (Direct)
  Date: 2026-06-08 | Code: M | equity_swap_involved: 0 | shares_owned_after: 335,257.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 16,563 shares of Common Stock (Direct)
  Date: 2026-06-08 | Code: M | equity_swap_involved: 0 | shares_owned_after: 351,820.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 18,400 shares of Common Stock at $4.01 per share (Direct)
  Date: 2026-06-08 | Code: F | equity_swap_involved: 0 | shares_owned_after: 333,420.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 11,175 shares of Restricted Stock Units (Derivative)
  Date: 2026-06-08 | Code: M | equity_swap_involved: 0 | shares_owned_after: 78,225.00 | transaction_form_type: 4 | Footnotes: F1, F3, F3
• Sold 11,172 shares of Restricted Stock Units (Derivative)
  Date: 2026-06-08 | Code: M | equity_swap_involved: 0 | shares_owned_after: 122,891.00 | transaction_form_type: 4 | Footnotes: F1, F4, F4
• Sold 12,125 shares of Restricted Stock Units (Derivative)
  Date: 2026-06-08 | Code: M | equity_swap_involved: 0 | shares_owned_after: 133,375.00 | transaction_form_type: 4 | Footnotes: F1, F5, F5
• Sold 16,563 shares of Restricted Stock Units (Derivative)
  Date: 2026-06-08 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F6, F6

Footnotes:

• F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
• F2: These shares were retained by Issuer via settlement on a net withholding basis in order to meet the tax withholding obligations of the reporting person in connection with the vesting of an installment of restricted stock units ("RSUs") granted to the reporting person on June 2, 2022, March 14, 2023, March 15, 2025, and March 16, 2026. None of these shares were sold in an open market transaction.
• F3: The initial number of restricted stock units granted shall vest in 16 equal quarterly installments starting on June 8, 2024, provided the Reporting Person continues to have a service relationship with the Issuer at such time. The restricted stock units have no expiration date.
• F4: The initial number of restricted stock units granted shall vest in 16 equal quarterly installments starting on June 8, 2025, provided the Reporting Person continues to have a service relationship with the Issuer at such time. The restricted stock units have no expiration date.
• F5: The initial number of restricted stock units granted shall vest in 12 equal quarterly installments starting on June 8, 2026, provided the Reporting Person continues to have a service relationship with the Issuer at such time. The restricted stock units have no expiration date.
• F6: Twenty-five percent (25%) of the restricted stock units shall vest on June 8, 2023, provided the Reporting Person continues to have a service relationship with the Issuer at such time. Thereafter, the remaining seventy-five percent (75%) of the restricted stock units shall vest in 12 equal quarterly installments starting on September 8, 2023, provided the Reporting Person continues to have a service relationship with the Issuer at such time. The restricted stock units have no expiration date.